Body composition changes in patients with schizophrenia

抗精神病药 氯氮平 内科学 医学 奥氮平 氟哌啶醇 安慰剂 精神分裂症(面向对象编程) 重量变化 利培酮 代谢综合征 精神病理学 内分泌学 精神科 减肥 肥胖 替代医学 病理 多巴胺
作者
B Nilsson,Anders Forslund,Roger Olsson,L. Hambreus,Frits‐Axel Wiesel
出处
期刊:European Psychiatry [Cambridge University Press]
卷期号:17: 186-186
标识
DOI:10.1016/s0924-9338(02)80800-8
摘要

Antipsychotic treatment is associated with metabolic disturbance. However, the degree to which metabolic alterations occur in treatment with different antipsychotics is unclear. Predictors of metabolic dysregulation are poorly understood and the association between metabolic change and change in psychopathology is uncertain. We aimed to compare and rank antipsychotics on the basis of their metabolic side-effects, identify physiological and demographic predictors of antipsychotic-induced metabolic dysregulation, and investigate the relationship between change in psychotic symptoms and change in metabolic parameters with antipsychotic treatment.We searched MEDLINE, EMBASE, and PsycINFO from inception until June 30, 2019. We included blinded, randomised controlled trials comparing 18 antipsychotics and placebo in acute treatment of schizophrenia. We did frequentist random-effects network meta-analyses to investigate treatment-induced changes in body weight, BMI, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, and glucose concentrations. We did meta-regressions to examine relationships between metabolic change and age, sex, ethnicity, baseline weight, and baseline metabolic parameter level. We examined the association between metabolic change and psychopathology change by estimating the correlation between symptom severity change and metabolic parameter change.Of 6532 citations, we included 100 randomised controlled trials, including 25 952 patients. Median treatment duration was 6 weeks (IQR 6–8). Mean differences for weight gain compared with placebo ranged from −0·23 kg (95% CI −0·83 to 0·36) for haloperidol to 3·01 kg (1·78 to 4·24) for clozapine; for BMI from −0·25 kg/m2 (−0·68 to 0·17) for haloperidol to 1·07 kg/m2 (0·90 to 1·25) for olanzapine; for total-cholesterol from −0·09 mmol/L (−0·24 to 0·07) for cariprazine to 0·56 mmol/L (0·26–0·86) for clozapine; for LDL cholesterol from −0·13 mmol/L (−0.21 to −0·05) for cariprazine to 0·20 mmol/L (0·14 to 0·26) for olanzapine; for HDL cholesterol from 0·05 mmol/L (0·00 to 0·10) for brexpiprazole to −0·10 mmol/L (−0·33 to 0·14) for amisulpride; for triglycerides from −0·01 mmol/L (−0·10 to 0·08) for brexpiprazole to 0·98 mmol/L (0·48 to 1·49) for clozapine; for glucose from −0·29 mmol/L (−0·55 to −0·03) for lurasidone to 1·05 mmol/L (0·41 to 1·70) for clozapine. Greater increases in glucose were predicted by higher baseline weight (p=0·0015) and male sex (p=0·0082). Non-white ethnicity was associated with greater increases in total cholesterol (p=0·040) compared with white ethnicity. Improvements in symptom severity were associated with increases in weight (r=0·36, p=0·0021), BMI (r=0·84, p<0·0001), total-cholesterol (r=0·31, p=0·047), and LDL cholesterol (r=0·42, p=0·013), and decreases in HDL cholesterol (r=–0·35, p=0·035).Marked differences exist between antipsychotics in terms of metabolic side-effects, with olanzapine and clozapine exhibiting the worst profiles and aripiprazole, brexpiprazole, cariprazine, lurasidone, and ziprasidone the most benign profiles. Increased baseline weight, male sex, and non-white ethnicity are predictors of susceptibility to antipsychotic-induced metabolic change, and improvements in psychopathology are associated with metabolic disturbance. Treatment guidelines should be updated to reflect our findings. However, the choice of antipsychotic should be made on an individual basis, considering the clinical circumstances and preferences of patients, carers, and clinicians.UK Medical Research Council, Wellcome Trust, National Institute for Health Research Oxford Health Biomedical Research Centre.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
vothuong完成签到,获得积分10
刚刚
方曦辉发布了新的文献求助10
刚刚
刚刚
科研小能手的应助被小巫采纳,获得200
刚刚
1秒前
852的应助被乐观笑南采纳,获得10
1秒前
高兴念真完成签到,获得积分10
1秒前
无名发布了新的文献求助10
1秒前
1秒前
优秀颦完成签到,获得积分10
2秒前
Camille发布了新的文献求助10
2秒前
得到的完成签到,获得积分10
2秒前
合适惜筠发布了新的文献求助10
2秒前
大菠萝完成签到,获得积分10
2秒前
Ry发布了新的文献求助10
3秒前
顺利向雁完成签到,获得积分10
3秒前
不成文发布了新的文献求助10
3秒前
3秒前
阳光汉堡完成签到,获得积分10
3秒前
wang5cl完成签到,获得积分10
4秒前
4秒前
愉快的孤晴完成签到,获得积分10
5秒前
5秒前
深情安青的应助被SanXing三醒采纳,获得10
5秒前
打打的应助被Besttin9799采纳,获得10
5秒前
CipherSage的应助被舒适平文采纳,获得10
5秒前
初景发布了新的文献求助10
6秒前
慕青的应助被kaida采纳,获得10
6秒前
SciGPT的应助被gonghe采纳,获得10
6秒前
6秒前
7秒前
7秒前
JamesPei的应助被XU采纳,获得10
7秒前
7秒前
eason楽发布了新的文献求助10
7秒前
蓝月半发布了新的文献求助10
7秒前
LUO发布了新的文献求助10
8秒前
8秒前
wyt完成签到,获得积分10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162755
求助须知:如何正确求助?哪些是违规求助? 9557016
关于积分的说明 21737907
捐赠科研通 7753093
什么是DOI,文献DOI怎么找? 3427901
关于科研通互助平台的介绍 2552719
邀请新用户注册赠送积分活动 2472528